Your browser doesn't support javascript.
loading
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Papp, K A; Griffiths, C E M; Gordon, K; Lebwohl, M; Szapary, P O; Wasfi, Y; Chan, D; Hsu, M-C; Ho, V; Ghislain, P D; Strober, B; Reich, K.
Affiliation
  • Papp KA; Probity Medical Research, 135 Union Street East, Waterloo, ON N2J1C4, Canada. kapapp@probitymedical.com
Br J Dermatol ; 168(4): 844-54, 2013 Apr.
Article in En | MEDLINE | ID: mdl-23301632
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Limits: Female / Humans / Male / Middle aged Language: En Journal: Br J Dermatol Year: 2013 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Limits: Female / Humans / Male / Middle aged Language: En Journal: Br J Dermatol Year: 2013 Document type: Article Affiliation country: Country of publication: